3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

Harmony Biosciences (HRMY) has been identified as a compelling growth stock, earning a Zacks Growth Score of B and a Zacks Rank #2 (Buy) due to strong financial metrics. The company projects 22.5% EPS growth this year, significantly exceeding the 19.1% industry average, alongside a robust 10% year-over-year cash flow growth, contrasting with the industry's -4.7% average. Additionally, positive earnings estimate revisions, with current-year estimates rising 0.2% over the past month, further underscore HRMY's potential as an outperformer for growth investors.

Analysis

Harmony Biosciences (HRMY) presents a compelling growth case based on several key financial metrics that significantly outperform industry benchmarks. The company is projected to achieve 22.5% EPS growth this year, which is notably higher than the 19.1% industry average, indicating strong profitability momentum. This is further supported by robust cash flow generation, with current year-over-year cash flow growth at 10%, a stark contrast to the industry's average contraction of -4.7%. This superior cash flow suggests a strong capacity to fund future growth internally. Reinforcing this positive outlook, the Zacks Consensus Estimate for current-year earnings has been revised upward by 0.2% in the past month. The combination of a Zacks Rank #2 (Buy) and a Growth Score of B, underpinned by these strong earnings and cash flow figures, positions the company as a potential outperformer in its sector.

Key Decisions for Investors

• Given the company's superior projected EPS growth and robust cash flow generation relative to its industry, growth-focused investors may find HRMY an attractive addition to their portfolios.
• Investors should closely monitor upcoming earnings reports to validate that the projected 22.5% EPS growth is on track and that the company maintains its positive cash flow trajectory.
• While the fundamentals appear strong, it is crucial to recognize the inherent volatility of growth stocks and consider position sizing carefully to manage the above-average risk mentioned in the report.